The $195M PRV sale provides a meaningful cash runway extension without dilution. Monitor for pipeline catalysts (DNL126, DNL593, DNL952) and any updates on the HSR clearance timeline. The cash strengthens Denali's ability to advance its clinical programs, but execution risk remains.
Price Chart
Executive Summary
Denali Therapeutics announced the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $195 million in gross proceeds. The PRV was awarded following FDA approval of AVLAYAH for Hunter syndrome in March 2026. The non-dilutive cash infusion strengthens Denali's financial flexibility and will fund its clinical pipeline, including programs for lysosomal storage disorders and neurodegenerative diseases.
Key Financial Metrics
Key Facts
- Denali entered a definitive agreement to sell its Rare Pediatric Disease PRV for $195 million gross proceeds.
- The PRV was awarded after FDA accelerated approval of AVLAYAH (tividenofusp alfa-eknm) for Hunter syndrome in March 2026.
- Proceeds will support Denali's TransportVehicle-enabled clinical pipeline, including DNL126, DNL593, DNL952, and DNL628.
- The transaction is subject to customary closing conditions, including HSR Act waiting period expiration.
Financial Impact
$195 million non-dilutive cash infusion, representing ~5.3% of Denali's $3.7B market cap.
Risk Factors
- PRV sale is subject to HSR waiting period and customary closing conditions.
- Pipeline programs are still in clinical/IND-enabling stages with no guarantee of success.
- Historical stock performance on DNLI has been poor, with negative average returns following prior reports.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3314101 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | Insider Cluster | $21.57 $20.06 | ▼ −7.00% | ▼ −6.34% | $20.00 (−7.28%) |
Sep 4, 2026 27d ago | Insider Cluster | $22.08 $20.38 | ▼ −7.70% | ▼ −6.58% | $20.00 (−9.42%) |
Aug 6, 2026 8w ago | 8-K | $24.83 $24.40 | ▼ −1.73% | ▼ −2.13% | $20.00 (−19.45%) |
Jul 27, 2026 9w ago | Press Release | $24.05 $23.15 | ▲ +3.74% | ▲ +6.01% | $20.00 (+16.84%) |
Jun 18, 2026 15w ago | 8-K | $23.31 $24.73 | ▲ +6.09% | ▲ +7.76% | $20.00 (−14.20%) |
Jun 18, 2026 15w ago | Press Release | $23.31 $24.73 | ▲ +6.09% | ▲ +7.76% | $20.00 (−14.20%) |
Jun 11, 2026 16w ago | Institutional Cluster | $21.02 $23.49 | ▲ +11.75% | ▲ +11.32% | $20.00 (−4.85%) |
May 21, 2026 19w ago | Press Release | $18.64 $20.41 | ▼ −9.50% | ▼ −7.84% | $20.00 (−7.30%) |
May 7, 2026 21w ago | Press Release | $19.62 $19.39 | ▼ −1.17% | ▼ −2.64% | $20.00 (+1.94%) |
Apr 3, 2026 26w ago | 8-K | $19.38 $19.42 | ▲ +0.21% | ▼ −3.93% | $20.00 (+3.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access